2024-08-14T13:28:25+00:00 2023-09-30 390859910 Baker Tilly Advisory Group LP 225 South 6th St Suite 2300 Minneapolis MN 55402 990 2022-10-01 840865803 NATIONAL MARROW DONOR PROGRAM NATI 7634065800 500 N 5TH ST MINNEAPOLIS MN 554011206 Katherine Heyerdahl CHIEF FINANCIAL OFFICER 7634065800 2024-08-14 true true Karen A Gries P00078514 6128764500 2024-07-31 2022 2024-08-08 14:25:15Z NMDP Katherine Heyerdahl 500 N 5TH ST MINNEAPOLIS MN 554011206 578283764 false X WWW.BETHEMATCH.ORG X 1981 CO WE SAVE LIVES THROUGH CELLULAR THERAPY. 16 16 1651 14591 202398 113302 64335916 59636648 434102011 508370767 2293761 9770958 102365 205398 500834053 577983771 1913720 6569319 0 180389634 211703987 0 4299168 326568329 352883430 508871683 571156736 -8037630 6827035 311842955 352274534 129567932 154795316 182275023 197479218 X See Schedule O: false false 326744866 3999996 486940997 TRANSPLANT: AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. CURRENTLY THERE ARE MORE THAN 9 MILLION TOTAL POTENTIAL U.S. DONORS ON THE NMDP REGISTRY. NMDP FACILITATES ALL UNRELATED TRANSPLANTS IN THE U.S., ASSISTING DOCTORS IN SEARCHING MORE THAN 41 MILLION POTENTIAL DONORS WORLDWIDE. NMDP HAS FACILITATED MORE THAN 125,000 TRANSPLANTS SINCE 1987. 65608785 299612 21500197 RESEARCH: RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, NMDP Foundation IS PROUD TO INVEST IN RESEARCH THROUGH: THE AMY STRELZER MANASEVIT RESEARCH PROGRAM (AMY PROGRAM): OUR FLAGSHIP RESEARCH FELLOWSHIP, THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST-DISEASE AND INFECTION). IN 2023, WE FUNDED THE WORK OF 12 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP NMDP PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, NMDP FOUNDATION HAS INVESTED NEARLY $12.5 MILLION TO HELP LAUNCH THE CAREERS OF 49 YOUNG PHYSICIAN-SCIENTISTS. AFTER RECEIVING THEIR AMY SCHOLAR AWARDS, THIS GROUP HAS GONE ON TO WIN MORE THAN $250 MILLION IN SUBSEQUENT GOVERNMENT GRANT FUNDING TO PURSUE THE DISCOVERIES THAT WILL HELP PATIENTS LIVE LONGER, HEALTHIER LIVES AFTER CELL THERAPY. TODAY, THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION. DONOR FOR ALL: THIS SERIES OF TRANSFORMATIONAL MULTI-CENTER STUDIES ARE TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR. ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION. NMDP'S CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH (CIBMTR): A PARTNERSHIP WITH THE MEDICAL COLLEGE OF WISCONSIN IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. NMDP Foundation HELPS TO FUND VARIOUS OTHER INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR. 48671415 0 0 RECRUITMENT: THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 41 MILLION POTENTIAL ADULT DONORS AND MORE THAN 800,000 CORD BLOOD UNITS WORLDWIDE. THE BEST MATCH FOR A PATIENT IS TYPICALLY SOMEONE WHO SHARES THEIR ETHNIC BACKGROUND. IMPROVING THE ETHNIC DIVERSITY OF THE NMDP REGISTRY IMPROVES ALL PATIENTS' ODDS OF FINDING THEIR BEST MATCH, REGARDLESS OF ETHNIC BACKGROUND. PEOPLE BETWEEN THE AGES OF 18 AND 35 ARE MOST URGENTLY NEEDED. RESEARCH HAS SHOWN THAT CELLS FORM YOUNGER DONORS LEAD TO BETTER LONG-TERM SURVIVAL FOR PATIENTS. IN FY23, MORE THAN 330,000 POTENTIAL DONORS JOINED THE NMDP REGISTRY AND MORE THAN 4,200 UMBILICAL CORD UNITS WERE ADDED TO THE REGISTRY. 22381318 2269711 70427 PUBLIC AWARENESS: NMDP PARTNERS WITH NMDP FOUNDATION TO ADVANCE VARIOUS INITIATIVES TIED TO THE SHARED MISSION. THESE PROGRAMS INCLUDE: NMDP PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, NMDP PEER CONNECT PROGRAM, NMDP SURVIVORSHIP PROGRAM, NMDP SICKLE CELL WARRIOR PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. NMDP Foundation RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES. 22381318 2269711 70427 463406384 true true false true false false false false false true false true false true true false true false true true true false false false false false true false true false false false false false false false false false false false false true true true true false false true X 1500 0 true 1651 true true true true MX CJ false false false false false false false false true false X 16 16 true false false false false false false true true false false true true true true true true true true false CA FL GA AL HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA AR WV WI X Katherine Heyerdahl 7634065800 500 N 5TH ST MINNEAPOLIS MN 554011206 BRIAN J REITHEL CHAIR 1.0 0 X X 0 0 0 Judy GASSON Vice Chair 1.0 0 X X 0 0 0 KRISHNA Komanduri Secretary 1.0 0 X X 0 0 0 ROBERT SOIFFER IMMEDIATE PAST CHAIR 1.0 0 X X 0 0 0 ABBY WEST DIRECTOR 1.0 0 X 0 0 0 ANNE McGeorge DIRECTOR 1.0 0 X 0 0 0 Elizabeth SHPALL DIRECTOR 1.0 0 X 0 0 0 Garheng KONG DIRECTOR 1.0 0 X 0 0 0 LAURIE STRONGIN DIRECTOR 1.0 0 X 0 0 0 LYNN Abrahamsen DIRECTOR 1.0 0 X 0 0 0 Melinda Caltabiano DIRECTOR 1.0 0 X 0 0 0 Michael LANG DIRECTOR 1.0 0 X 0 0 0 Ravyn MILLER DIRECTOR 1.0 0 X 0 0 0 Stephanie LEE DIRECTOR 1.0 0 X 0 0 0 URI Herzberg DIRECTOR 1.0 0 X 0 0 0 VICKI Rasmusen DIRECTOR 1.0 0 X 0 0 0 AMY RONNEBERG Chief Executive Officer 48.0 2.0 X 1487126 0 25812 KRISTA DUSIL CHIEF FINANCIAL OFFICER 49.0 1.0 X 565014 0 52445 STEVEN DEVINE Chief Medical Officer 50.0 0 X 864390 0 51118 Erica Jensen SVP, Registry Growth & Development 49.0 0 X 586063 0 53978 Jamie Margolis SVP, Donor Services 49.5 0 X 593226 0 33771 Jeffery Auletta SVP, Health Equity and Chief Scientific Director 49.0 0 X 633391 0 56926 Joy King Chief Advancement Officer 30.0 20.0 X 337951 225301 49675 Julie Smolich SVP, PATIENT & PROVIDER SERVICES 49.0 0 X 736297 0 53528 Michael McCullough Chief Digital and Information Officer 47.0 0 X 674040 0 51411 Brian Lindberg CHIEF ADMINISTRATIVE OFFICER 49.0 0 X 829778 0 54290 Heather Stefanski Vice President, Medical Service 50.0 0 X 498257 0 48174 Huy Pham Medical Director - Strategic Initiative Only 50.0 0 X 482539 0 49624 John Miller Vice President, Medical & Quality Services 50.0 0 X 685062 0 33590 Patricia Jones SVP, Human Resources 49.0 0 X 662117 0 54038 gina graves former officer 0.0 0.0 X 358453 0 36354 jeffrey chell former officer 0.0 0.0 X 100002 0 0 10093706 225301 704734 517 true true false THE EMMES CORPORATION 401 N WASHINGTON STREET SUITE 700 ROCKVILLE MD 20850 RESEARCH DATA COLLECTION 11679576 MMS USA INVESTMENTS INC 35 WEST WACKER DRIVE CHICAGO IL 60601 NATIONAL CAMPAIGN MEDIA FEES 7106128 COHERENT SOLUTIONS INC 1600 UTICA AVE S STE 120 MINNEAPOLIS MN 55416 IT SERVICES 5943412 HOLLSTADT AND ASSOCIATES INC 1305 CORPORATE CENTER DRIVE suite 310 eagan MN 55121 BUSINESS CONSULTING 5372445 EPLUS TECHNOLOGY 13595 DULLES TECHNOLOGY DRIVE HERNDON VA 20171 IT Services 3862152 178 3659840 55397011 579797 59636648 SEARCH/PROCUREMENT REV 621990 508370767 508370767 0 0 0 0 508370767 3004501 3004501 328324 125926 202398 0 202398 202398 6886373 54151 145993 28074 6740380 26077 6766457 6766457 MISCELLANEOUS 900099 3000 3000 0 0 0 0 3000 577983771 508370767 202398 9773958 6269707 6269707 299612 299612 6565710 6565710 87613 87613 162884859 116566810 44822111 1495938 9868634 6997702 2775895 95037 20046170 12367313 7520757 158100 12251001 8756336 3384609 110056 2748495 2748095 400 132583 132583 610140 610140 138679 138679 20592996 17584679 3008317 0 8402952 5596597 2806355 3120185 2969696 28466 122023 40673629 28381608 10582965 1709056 4129965 377815 3730325 21825 4032699 2847886 1181191 3622 1677314 403677 1273637 1641654 1641654 17834840 8172245 9085778 576817 1426090 234005 1189968 2117 Medical Services Expense 218084683 218084683 DONOR RECRUITMENT SERVICES 13571293 13571293 FORMS COMPLETION & RESEARCH 12232058 12232058 1833175 1082522 746476 4177 571156736 463406384 103451184 4299168 19519183 41177059 14949494 8384238 54609192 70960978 0 0 0 0 9871161 10391345 169715350 92784351 81849311 76930999 97423013 108433532 0 26473234 28667436 7148367 7328947 311842955 352274534 81061814 104956882 1860036 2788616 0 0 46646082 47049818 129567932 154795316 X 182275023 197479218 182275023 197479218 311842955 352274534 6827035 8259283 117877 0 X false true X true true true X 55288081 50072983 51162924 64021069 59636648 280181705 386677912 385698701 388404186 434102011 508370767 2103253577 0 0 0 441965993 435771684 439567110 498123080 568007415 2383435282 0 0 0 0 0 0 0 0 53540708 63611960 76145656 193298324 0 0 53540708 63611960 76145656 193298324 2190136958 3257641 3232070 2680739 2976195 3004500 15151145 0 3257641 3232070 2680739 2976195 3004500 15151145 65221 85122 83992 82787 113302 430424 0 0 0 1800 3000 4800 445288855 439088876 442331841 501183862 571128217 2399021651 0.9129 0.9411 0.01 0.0066 X Schedule A, Part III, Line 12 Other Income DESCRIPTION - MISCELLANEOUS, COLUMN A - , COLUMN B - , COLUMN C - , COLUMN D - 1800.0, COLUMN E - 3000.0, COLUMN F - 4800.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false false false false true 898244 false true 194368 1092612 true Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY A non-profit leader in bone marrow transplant, NMDP creates essential connections between volunteers and elected officials to inspire action and accelerate innovation to find life-saving cures for blood cancer and disorders. NMDP is entrusted to operate the national registry of the world's most diverse bone marrow donors and works with elected officials at the state and federal level to expand access to treatment so that every patient can receive their life saving transplant. 63603165 31674434 31928731 11644556 4148468 7496088 23029660 16783526 6246134 71437969 40177923 31260046 76930999 PRI - FOREIGN SUBSIDIARIES 18683574 C PRI - MAGENTA 6149986 C PRI - NMDP AUXILIARY SERVICES 3833876 C 28667436 LONG TERM CAPITAL LEASE 40017878 DEFERRED COMPENSATION & RENT PAYABLE 7031940 47049818 X 586889104 8259283 1811574 10070857 576818247 138679 1026845 1165524 577983771 571802786 1811574 1811574 569991212 138679 1026845 1165524 571156736 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER ASC 740: THE INTERNAL REVENUE SERVICE HAS DETERMINED THAT NMDP AND NMDP FOUNDATION ARE TAX-EXEMPT ORGANIZATIONS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE NOT-FOR-PROFIT STATUS OF THE PROGRAM AND NMDP FOUNDATION ARE CONSIDERED TAX POSITIONS UNDER FASB ASC 740, INCOME TAXES. THE ORGANIZATION FOLLOWS THE ACCOUNTING STANDARDS FOR CONTINGENCIES IN EVALUATING UNCERTAIN TAX POSITIONS. THIS GUIDANCE PRESCRIBES RECOGNITION THRESHOLD PRINCIPLES FOR THE FINANCIAL STATEMENT RECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN ON A TAX RETURN THAT ARE NOT CERTAIN TO BE REALIZED. NO LIABILITY HAS BEEN RECOGNIZED BY THE ORGANIZATION FOR UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2023, OR 2022. THE ORGANIZATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE AUTHORITIES. NMDPCS IS TREATED AS A DISREGARDED ENTITY FOR INCOME TAX REPORTING PURPOSES. AS SUCH, NMDPCS'S INCOME, LOSSES AND CREDITS ARE INCLUDED IN THE TAX RETURN OF ITS SOLE MEMBER AND PARENT, NMDP. NMDPAS IS A REGARDED ENTITY FOR TAX PURPOSES AND FILES A SEPARATE TAX RETURN. CLEAR IS AN EXEMPTED COMPANY OPERATING SUBJECT TO THE COMPANIES LAW (REVISED) OF CAYMAN ISLANDS AND IS INCLUDED IN THE TAX RETURN OF NMDP. BTMM IS TREATED AS A FOREIGN CORPORATION FOR U.S INCOME TAX REPORTING PURPOSES. BTMM FILES A SEPARATE TAX RETURN IN MEXICO. Schedule D, Part XI, Line 2(d) Other revenues in audited financial statements not in form 990 Intercompany Elimination: Products and services - 1811574 Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements NMDP Foundation strategic contribution - 676173 Contribution for Compensation - 350672 Schedule D, Part XII, Line 2(d) Other expenses in audited financial statements not in form 990 Intercompany Elimination: Products and services - 1811574 Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements NMDP Foundation strategic contribution - 676173 Contribution for Compensation - 350672 true Central America and the Caribbean 1 0 Program Services CAPTIVE INSURANCE 2365163 Central America and the Caribbean 1 0 MAINTAINING OFFICES CAPTIVE INSURANCE 192477 Central America and the Caribbean 1 0 Investments CAPTIVE INSURANCE 1881 Central America and the Caribbean 1 0 Program Services MEDICAL 3594054 East Asia and the Pacific 0 0 Program Services MEDICAL 2005025 Europe (Including Iceland and Greenland) 0 0 Program Services MEDICAL 37395560 Europe (Including Iceland and Greenland) 0 0 Grantmaking RESEARCH 299612 Middle East and North Africa 0 0 Program Services MEDICAL 5047120 North America (Canada & Mexico only) 1 0 Program Services MEDICAL 724000 North America (Canada & Mexico only) 1 0 Investments MEDICAL 2194202 North America (Canada & Mexico only) 1 0 Program Services MEDICAL 6530719 Russia and Neighboring States 0 0 Program Services MEDICAL 18390 South America 0 0 Program Services MEDICAL 3032177 South Asia 0 0 Program Services MEDICAL 61420 Sub-Saharan Africa 0 0 Program Services MEDICAL 10667 7 0 0 0 7 0 63472467 0 63472467 Europe (Including Iceland and Greenland) RESEARCH 284951 WIRE TRANSFER Europe (Including Iceland and Greenland) Conference sponsor 14661 WIRE TRANSFER 2 0 true false true false false true Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds Schedule F, Part I, Line 2: Before any check is cut for event or other sponsorship, the documentation around what the expenditure is for is reviewed and routed through our oracle procurement module approvals following our organization's chart of authority. Strict protocols are followed for any activity occurring in countries sanctioned by US Department of Treasury. PROCEDURE FOR MONITORING USE OF GRANT FUNDS OUTSIDE U.S. INTERNATIONAL TRANSPLANT CENTERS THROUGHOUT THE WORLD WORK IN AFFILIATION WITH NMDP TO FIND DONORS FOR THE PATIENTS IN NEED. PROGRESS REPORTS ARE SUBMITTED BY RESEARCH SCIENTISTS FOR NMDP'S REVIEW. IF THE PROGRESS IS SATISFACTORY, FUNDS ARE DISTRIBUTED TO THE SCIENTISTS. IF NO PROGRESS REPORT IS SUBMITTED OR THE PROGRESS IS DEEMED UNSATISFACTORY, NO FUNDS WILL BE DISTRIBUTED. Schedule F, Part I, Line 3: TOTAL EXPENDITURES BY REGION THE TOTAL EXPENDITURES BY REGION CALCULATED AMOUNT EQUALS THE CHECKS THAT ACCOUNTS PAYABLE CUT DURING FY2023. Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual true SICKLE CELL CONSORTIUM 2265 LEXINGTON LANE CUMMING GA 30040 474771677 501(C)(3) 5000 SPONSORSHIP FOR SC3 ANNUAL WARRIORS CONVENTION CORD BLOOD ASSOCIATION 211 GARFIELD STREET GENEVA IL 60134 814173015 501(C)(3) 25000 CONFERENCE SPONSOR NMDP FOUNDATION (FORMERLY BE THE MATCH FOUNDATION) 500 N 5TH STREET Minneapolis MN 55401 411704734 501(C)(3) 2215740 HRSA PATIENT ASSISTANCE FUNDING 3 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. PROCEDURE FOR MONITORING THE USE OF GRANT FUNDS INSIDE THE U.S. BEFORE ANY CHECK IS CUT FOR EVENT OR OTHER SPONSORSHIP, THE DOCUMENTATION AROUND WHAT THE EXPENDITURE IS FOR IS REVIEWED AND ROUTED THROUGH OUR ORACLE PROCUREMENT MODULE APPROVALS FOLLOWING OUR ORGANIZATION'S CHART OF AUTHORITY. X X X X false true false false false false false false false gina graves former officer 219405 0 127022 0 12026 0 25790 0 10564 0 394807 0 0 0 jeffrey chell former officer 0 0 0 0 100002 0 0 0 0 0 100002 0 0 0 AMY RONNEBERG Chief Executive Officer 726731 0 738407 0 21988 0 25790 0 22 0 1512938 0 0 0 STEVEN DEVINE Chief Medical Officer 453909 0 379871 0 30610 0 25790 0 25328 0 915508 0 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER 331370 0 221373 0 12271 0 25790 0 26655 0 617459 0 0 0 Julie Smolich SVP, PATIENT & PROVIDER SERVICES 382830 0 336687 0 16780 0 25790 0 27738 0 789825 0 0 0 Michael McCullough Chief Digital and Information Officer 352682 0 307587 0 13771 0 25790 0 25621 0 725451 0 0 0 Jeffery Auletta SVP, Health Equity and Chief Scientific Director 370351 0 243044 0 19996 0 25790 0 31136 0 690317 0 0 0 Erica Jensen SVP, Registry Growth & Development 301504 0 272527 0 12032 0 25790 0 28188 0 640041 0 0 0 Jamie Margolis SVP, Donor Services 310149 0 272531 0 10546 0 25790 0 7981 0 626997 0 0 0 Joy King Chief Advancement Officer 176658 117772 154725 103150 6568 4379 15474 10316 14331 9554 367756 245171 0 0 Brian Lindberg CHIEF ADMINISTRATIVE OFFICER 435253 0 374595 0 19930 0 25790 0 28500 0 884068 0 0 0 John Miller Vice President, Medical & Quality Services 406835 0 246115 0 32112 0 25790 0 7800 0 718652 0 0 0 Patricia Jones SVP, Human Resources 336070 0 297571 0 28476 0 25790 0 28248 0 716155 0 0 0 Heather Stefanski Vice President, Medical Service 320037 0 163876 0 14344 0 25790 0 22384 0 546431 0 0 0 Huy Pham Medical Director - Strategic Initiative Only 343799 0 134914 0 3826 0 25790 0 23834 0 532163 0 0 0 Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Organization offers a supplemental benefits plan (the Supplemental Plan) for its officers, senior vice presidents and vice presidents. All Supplemental Plan participants received $750,000 in life insurance, long-term disability and long-term care insurance. The supplemental plan was created in accordance with applicable provisions of the Internal Revenue Code (IRC Sec 7702). Premiums are paid by the Organization and are treated as taxable income to plan participants. Future benefits received under the plan, if any, will not be taxable. Plan balances are personally owned by the plan participants immediately and are not subject to a risk of forfeiture; as such, the plan assets are not recorded on the Organization's consolidated financial statements. Form 990, Part III, Line 1 AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. . OUR MISSION: WE SAVE LIVES THROUGH CELL THERAPY. OUR VISION: CREATE A WORLD WHERE EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. THE NMDP FOUNDATION RAISES FUNDS FOR THREE PROGRAMS CRITICAL TO OUR LIFE-SAVING MISSION: TRANSPLANT RESEARCH, PATIENT FINANCIAL ASSISTANCE AND DONOR RECRUITMENT. SOME OF THE LIFE-CHANGING WORK THAT WE'RE DOING IS SOLEY FUNDING BY OUR COMMUNITY OF SUPPORTERS. WE CONDUCT RESEARCH THROUGH OUR RESEARCH PROGRAM, CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH) IN COLLABORATION WITH THE MEDICAL COLLEGE OF WISCONSIN. OUR RESEARCH LEADS TO MORE LIVES SAVED AND AN ENRICHED QUALITY OF LIFE FOR THOUSANDS OF PATIENTS. THROUGH THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM AND OTHER RESEARCH GRANTS, OUTSTANDING EARLY-CAREER RESEARCHERS ARE DOING INNOVATIVE WORK TO FIND SOLUTIONS TO THE COMPLICATIONS THAT CAN ARISE AFTER TRANSPLANT. THEY'RE DEVELOPING TREATMENT APPROACHES THAT WILL HELP THE NEXT GENERATION OF TRANSPLANT PATIENTS LIVE LONGER, HEALTHIER LIVES. PATIENT FINANCIAL ASSISTANCE HELPS COVER TRANSPLANT-RELATED COSTS NOT COVERED BY INSURANCE THAT CAUSE SIGNIFICANT HARDSHIP OR EVEN PREVENT PATIENTS FROM MOVING FORWARD WITH TRANSPLANT. COSTS LIKE TRANSPORTATION, LODGING, LOST WAGES AND PRESCRIPTIONS. NMDP CONNECTS PATIENTS WITH A MATCHING, UNRELATED DONOR, A SELFLESS STRANGER WHO CAN STEP UP AND DONATE THEIR HEALTHY BLOOD STEM CELLS TO GIVE THEM THE CHANCE AT A LIFE-SAVING TRANSPLANT. Form 990, Part III, Line 4d Description of other program services (Expenses $ 22,381,318 including grants of $ 2,269,711)(Revenue $ 70,427) PUBLIC AWARENESS: NMDP PARTNERS WITH NMDP FOUNDATION TO ADVANCE VARIOUS INITIATIVES TIED TO THE SHARED MISSION. THESE PROGRAMS INCLUDE: NMDP PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, NMDP PEER CONNECT PROGRAM, NMDP SURVIVORSHIP PROGRAM, NMDP SICKLE CELL WARRIOR PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. NMDP Foundation RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES. Form 990, Part VI, Line 2 FAMILY/BUSINESS RELATIONSHIPS AMONGST INTERESTED PERSONS The following Directors of the NMDP have a reportable business relationship: Anne McGeorge and Amy Ronneberg (Ms. McGeorge and Ms. Ronneberg were both voting directors of Magenta Therapeutics during FY2023). The following Directors of NMDP have a reportable business relationship: Anne McGeorge and Amy Ronneberg (Ms. McGeorge and Ms. Ronneberg were both voting directors of CLEAR Insurance, Ltd. during FY2023). Form 990, Part VI, Line 1a Delegate broad authority to a committee The NMDP Bylaws state: "The Executive Committee shall at all times include the Chair of the Board, the Immediate Past Chair (when in office), the Chair-Elect (when in office), the Secretary, the Chief Executive Officer, and any Government Representatives. Any and all additional members of the Executive Committee shall be Voting Directors, except the Chief Executive Officer and Government Representatives, who shall serve as non-voting ex officio members of the committee. The Executive Committee shall, to the extent allowed by applicable law, have the authority of the Board in the oversight of the business of the Corporation between meetings of the full Board and shall have such other authority and responsibilities as set forth in the Executive Committee Charter." The Executive Committee Charter states: "The Executive Committee shall, to the extent determined by the Board of Directors, have the authority of the Board in the oversight of the business of the Corporation between meetings of the full Board. The Executive Committee shall manage the business of the Corporation and direct and coordinate the work activities of committees between meetings of the Board. The Executive Committee shall also review key Board-level policies and procedures on a periodic basis and recommend new or modified policies and initiatives. With the Board, the Executive Committee is responsible for oversight of the strategic planning process, developing a calendar for Board activities, and providing guidance to the Board and Corporation staff regarding the appropriate roles of each. The Executive Committee, in close coordination with the Audit & Finance Committee, shall monitor the financial integrity of operations, including evaluating performance against the Corporation's budget and strategic and business plans. In addition, the Executive Committee shall represent the Corporation in its interactions with other organizations, Congress, federal agencies, participating centers, constituent groups, professional organizations, and the public." Form 990, Part VI, Line 11b Review of form 990 by governing body Form 990 review process: The organization contracted with the outside public accounting firm, Baker Tilly, to prepare the Form 990. Preparing the details and supporting reports for the return is a collaborative effort among a small group of individuals in the financial reporting & compliance area of finance, internal audit and human resources. Once a draft is received back from Baker Tilly, it is reviewed by the team that pulled the details together, Director, Finance and Corporate Controller, and NMDP Chief Financial Officer. The NMDP CHIEF ADMINISTRATIVE OFFICER also reviews the governance sections. A copy of the return is provided to the organization's audit and finance committee and board of directors prior to filing. Form 990, Part VI, Line 12c Conflict of interest policy The Conflict of Interest Policy states the following: "The existence of an actual or potential conflict of interest turns on the specific facts and circumstances in each case. If a Member has an interest which may conflict with those of the Organizations, he or she must immediately disclose the matters and discuss them fully and frankly with the applicable Organization's full Board or its Executive Committee, as set forth in detail below. A Member must not participate in any matter in which that Member may have an actual or potential conflict of interest without the express approval of the applicable Organization's Board of Directors or Executive Committee of the Board of Directors (Executive Committee). All Members must disclose to the applicable Organization's Board of Directors or Executive Committee all conflicts of interest and reportable relationships, and must annually complete and submit the Conflict of Interest Questionnaire which is required by this Policy. Whenever in the course of events a Member's circumstances change such that the Member knows or has reason to believe that the Member may have an actual or perceived conflict of interest, such Member shall promptly disclose the potential conflict to the applicable Organization's Board of Directors or Executive Committee. For the purposes of this Article, a Member may formally disclose a conflict or reportable relationship to the NMDP Chief Executive Officer (CEO), the Chief Advancement Officer, or the NMDP Chief Administrative Officer and General Counsel (CAO), as applicable, who shall inform the applicable Organization's Board of Directors or Executive Committee for resolution. As noted herein, if the potential conflict involves a Director or Committee Member, that Director or Committee Member shall not participate in or vote upon such matters until the question of the existence of the conflict of interest has been resolved in accordance with this Policy. Likewise, an officer or key employee may not become substantially involved in decision-making involving any covered litigation, contract or transaction until the resolution of the matter in accordance with this Policy." Form 990, Part VI, Line 15a Process to establish compensation of top management official The NMDP Bylaws state: "The Compensation Committee shall be comprised only of Voting Directors and shall include the Chair of the Board and at least one (1) non-officer Board member as voting committee members. The Compensation Committee shall review and evaluate the overall compensation and benefit structure of the Corporation and shall have such other authority and responsibilities as set forth in the Compensation Committee Charter." The Compensation Committee Charter states: "The Committee shall review and evaluate the overall compensation and benefit structure of the Corporation, and approve and adopt a compensation philosophy and principles consistent with the Corporation's non-for-profit status (the "Compensation Philosophy and Principles"). The Committee shall conduct the Chief Executive Officer ("CEO") performance evaluation. The Committee shall make CEO total compensation and benefit recommendations to the Executive Committee, consistent with the Compensation Philosophy and Principles. In making compensation and benefit recommendations for the CEO, the Committee shall utilize, among other things, comparability data for compliance with IRS Intermediate Sanction provisions so as to allow the Corporation to take advantage of the rebuttable presumption of reasonableness. On a periodic basis, the Committee shall obtain comparability data from an independent compensation consultant. In addition, the Committee shall advise the CEO in his/her evaluation of and decisions regarding the compensation of and benefits for senior Corporation employees, as well as the President (or equivalent leader) of any subsidiary of the Corporation reporting to the CEO (together, "Senior Leadership"). In advising the CEO in making his/her compensation and benefit decisions for Senior Leadership, the Committee shall ensure that such decisions are consistent with the Compensation Philosophy and Principles, and utilize, among other things, comparability data for compliance with IRS Intermediate Sanction provisions. If decisions proposed by the CEO are outside the parameters of the Compensation Philosophy and Principles, the CEO must obtain the Committee's approval prior to implementation." Form 990, Part VI, Line 19 Required documents available to the public How documents are made available to the public: The conflict of interest policy, articles of incorporation and consolidated audited financial statements are available to the public upon request. Summary financial statements are also included in our annual report, which is mailed to key stakeholders and posted on our website. Additionally, articles of incorporation are available through the MN office of the secretary of state, and consolidated audited financial statements may be obtained at the MN office of the attorney general. Form 990, Part XII, Line 2c THE ORGANIZATION HAS NEITHER CHANGED ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR. NMDP COLLECTION SERVICES LLC (FORMERLY BE THE MATCH COLLECTION SERVICES LLC ) 500 N 5TH ST MINNEAPOLIS MN 554011206 811241889 CELL THERAPY MN 1813943 4402443 NMDP NMDP FOUNDATION (FORMERLY BE THE MATCH FOUNDATION) 500 N 5TH ST MINNEAPOLIS MN 554011206 411704734 FUNDRAISING MN 501(c)(3) 7 NMDP true BE THE MATCH MX AC Veracruz av 93 101 Piso Cuidad De mexico condesa MX 06140 RECRUITMENT MX NMDP true CLEAR INSURANCE LTD 840865803 CAPTIVE INSURANCE CJ NMDP C Corporation 2655906 5082838 true NMDP AUXILIARY SERVICES LLC 500 N 5TH ST MINNEAPOLIS MN 554011206 811248190 CELL THERAPY MN NMDP C Corporation 0 234977 true true true true false false false false false false false false false false true true false true true false NMDP AUXILIARY SERVICES LLC A 325732 FMV NMDP FOUNDATION B 6215736 COST BE THE MATCH MEXICO B 2194202 COST NMDP FOUNDATION C 3439620 COST BE THE MATCH MEXICO C 220220 COST NMDP FOUNDATION N 156485 COST NMDP FOUNDATION O 1140000 COST BE THE MATCH MEXICO O 724000 COST BE THE MATCH MEXICO Q 1682656 COST CLEAR INSURANCE LTD R 3088364 COST NATIONAL MARROW DONOR PROGRAM 500 N 5TH ST MINNEAPOLIS MN 554011206 840865803 X 194368 898244 1092612 569713452 570806064 1000000 250000 0 92612 92612 NMDP Foundation 500 N 5TH ST Minneapolis MN 55401 411704734 X 0 0 0 18261426 18261426 1000000 250000 0 0 0